Zolinza Related Published Studies
Well-designed clinical trials possibly related to Zolinza (Vorinostat)
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. [2006.01]
Other research related to Zolinza (Vorinostat)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. [2009.10.06]
A phase 2 study of vorinostat in acute myeloid leukemia. [2009.10]
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. [2009.09.10]
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. [2009.09]
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. [2009.08.26]
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. [2009.08.15]
Development of vorinostat: current applications and future perspectives for cancer therapy. [2009.08.08]
Vorinostat in solid and hematologic malignancies. [2009.07.27]
Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. [2009.07.20]
A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. [2009.07]
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. [2009.05.01]
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. [2009.04.20]
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. [2009.04]
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. [2009.03.01]
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. [2009.01]
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. [2008.11.01]
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.11]
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. [2008.10.01]
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. [2008.10]
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. [2008.09.01]
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.07.30]
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. [2008.05.15]
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. [2008.05]
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. [2008.05]
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. [2008.05]
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. [2008.04.19]
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. [2008.03]
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. [2008.02.01]
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. [2008.02]
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. [2007.10]
Vorinostat in cutaneous T-cell lymphoma. [2007.09]
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. [2007.08.01]
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. [2007.07.20]
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. [2007.07]
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. [2007.06.15]
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. [2007.04.15]
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). [2007.01.01]
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. [2007.01]
Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. [2006.12]
Other possibly related research studies
Treatment of cutaneous T-cell lymphoma/mycosis fungoides. [2006.12]
Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy. [2007.02.15]
In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. [2007.03]
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. [2006.10.17]
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. [2006.09.15]
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. [2006.08.24]
Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. [2006.06]
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. [2006.08.15]
Human endometrial cytodifferentiation by histone deacetylase inhibitors. [2006.02]
Histone hyperacetylation is associated with amelioration of experimental colitis in mice. [2006.04.15]
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. [2006.04.01]
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. [2006.01.01]
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. [2006.01]
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. [2005.11]
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. [2005.03]
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. [2005.09.01]
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. [2005.12]
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. [2005.08.01]
[Histone deacetylase inhibitors as a new generation of anti-cancer agents] [2005.03.11]
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. [2005.06.10]
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. [2005.05]
Modulation of radiation response by histone deacetylase inhibition. [2005.05.01]
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. [2005.03.15]
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. [2005.06]
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. [2005.03]
Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. [2005.03.08]
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. [2004.09.15]
Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. [2004.09.15]
Suberanilohydroxamic Acid. Aton Pharma. [2004.07]
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. [2003.12.01]
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. [2003.09.01]
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. [2003.05.01]
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. [2003.02.18]
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. [2003.04.15]
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. [2002.03.05]
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. [2001]
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. [2000.10]
Discovery and development of SAHA as an anticancer agent. [2007.02.26]
Gateways to clinical trials. [2006.10]
Gateways to clinical trials. [2006.06]
Gateways to clinical trials. [2006.04]
Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. [2007.06]
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. [2007.06]
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. [2007.05.08]
Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. [2007.06.15]
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. [2007.05]
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. [2007.04]
Histone deacetylase inhibitors: biology and mechanism of action. [2007.01]
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. [2007.07]
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. [2007]
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. [2007.02]
Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. [2007.06]
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. [2007.07.01]
Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. [2007.07]
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. [2007.02]
Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). [2007.12.05]
Epigenetic alterations and cancer: new targets for therapy. [2007.10]
Histone deacetylase inhibitors: overview and perspectives. [2007.10]
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. [2008.02]
Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. [2007]
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. [2007.11.19]
|
